BioDelivery Sciences International isn't inventing new drugs, but it is looking for better ways to administer them. The development-stage firm takes already approved drugs that are normally delivered intravenously and reformulates them into buccal (absorbed by the inner cheek) and oral treatments. Drugs delivered via its BEMA and Bioral systems are being studied to treat such conditions as acute pain, nausea, and fungal infections. In 2009 BioDelivery Sciences gained FDA approval of its BEMA fentanyl candidate, ONSOLIS, which consists of a dissolving disc that delivers the cancer pain drug buccally. Swedish partner Meda AB markets the drug in the US and has commercialization rights in most other global markets.